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Stereotactic radiosurgery by gamma-knife (GK) is an attrac-
tive therapeutic option after failure of microsurgical removal
in patients with pituitary adenoma. In these tumors or rem-
nants of them, it aims to obtain the arrest of cell proliferation
and hormone hypersecretion using a single precise high dose
of ionizing radiation, sparing surrounding structures. The
long-term efficacy and toxicity of GK in acromegaly are only
partially known. Thirty acromegalic patients (14 women and
16 men) entered a prospective study of GK treatment. Most
were surgical failures, whereas in 3 GK was the primary treat-
ment. Imaging of the adenoma and target coordinates iden-
tification were obtained by high resolution magnetic reso-
nance imaging. All patients were treated with multiple
isocenters (mean, 8; range, 3–11). The 50% isodose was used in
27 patients (90%). The mean margin dose was 20 Gy (range,
15–35), and the dose to the visual pathways was always less
than 8 Gy. After a median follow-up of 46 months (range, 9–96),
IGF-I fell from 805 g/liter (median; interquartile range, 640–
994) to 460 g/liter (interquartile range, 217–654; P  0.0002),
and normal age-matched IGF-I levels were reached in 7
patients (23%). Mean GH levels decreased from 10 g/liter
(interquartile range, 6.4–15) to 2.9 g/liter (interquartile
range, 2–5.3; P < 0.0001), reaching levels below 2.5 g/liter in
11 (37%). The rate of persistently pathological hormonal levels
was still 70% at 5 yr by Kaplan-Meier analysis. The median
volume was 1.43 ml (range, 0.20–3.7). Tumor shrinkage (at
least 25% of basal volume) occurred after 24 months (range,
12–36) in 11 of 19 patients (58% of assessable patients). The rate
of shrinkage was 79% at 4 yr. In no case was further growth
observed. Only 1 patient complained of side-effects (severe
headache and nausea immediately after the procedure, with
full recovery in a few days with steroid therapy). Anterior
pituitary failures were observed in 2 patients, who already
had partial hypopituitarism, after 2 and 6 yr, respectively. No
patient developed visual deficits. GK is a valid adjunctive tool
in the management of acromegaly that controls GH/IGF-I hy-
persecretion and tumor growth, with shrinkage of adenoma
and no recurrence of the disease in the considered observa-
tion period and with low acute and chronic toxicity. (J Clin
Endocrinol Metab 88: 3105–3112, 2003)
RADIATION AS A treatment modality in pituitary ade-nomas is as old as surgical removal itself, being at-
tempted in the first years of the past century (1). Currently
it includes, besides fractionated conventional radiotherapy
(RT), radiosurgery by gamma-knife (GK) and by specially
modified linear accelerators and particle accelerators.
In the last 30 yr transsphenoidal surgery has emerged as
the initial treatment of choice for acromegaly, because it
affords relative safety and the fast reduction of both hor-
mone hypersecretion and tumoral mass. A variety of rea-
sons, including technical difficulty, caution near sensitive
structures, and tumor invasion of perisellar structures,
hamper successful radical resection in at least 30% of
operated patients. Medication, when effective and toler-
ated, has the drawbacks of a life-long and high cost
treatment.
RT has been regarded for a long time as the conventional
method for adjuvant therapy. Rates of tumor growth con-
trol have been reported to vary from 72–97% (2, 3),
whereas control of hormonal hypersecretion is less con-
sistent among different series, ranging from less than 5%
of IGF-I normalization (4) to 79% (5). The major drawbacks
of RT include the long delay before the desired effect (often
a decade) and serious side-effects, including a relatively
high rate of hypopituitarism (13–100%) (6 – 8), potential
cerebral necrosis (0 –3%) (5, 9), neurobehavioral sequelae
(10), low but still significant risks of optic neuropathy
(1–2%) (3, 11, 12), and induction of secondary tumor
(13, 14).
Radiosurgery, defined as highly precise circumscribed de-
livery of radiation to a target in a single session (15), per-
formed by either GK or other stereotactic modalities, has
been gaining acceptance in recent years to overcome the
limitations of RT. The goal is to collimate selectively to the
adenoma a high dose of radiation capable of influencing
the growth of the tumor and hypersecretion, with negligible
irradiation of surrounding normal tissue.
The control of adenoma growth alone that would be
enough in other tumoral indications is inadequate in the
secreting pituitary adenomas. Radiosurgery of acromegaly
to prove a valid therapeutic adjunct ought to correct de-
ranged GH secretion and reverse morbidity and excess mor-
tality by reducing GH below a threshold regarded as safe on
Abbreviations: GK, Gamma-knife; IFMA, immunofluorometric assay;
RT, radiotherapy; SA, somatostatin analog; UFC, urinary free cortisol.
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the basis of epidemiological studies (16, 17) and decreasing
IGF-I to age-adjusted concentrations.
Patients and Methods
Patients
Thirty acromegalic patients (14 women and 16 men) entered this pro-
spective open study from February 1993 to January 2001. All had active
disease according to the clinical picture, elevated GH levels not suppressible
below 1 g/liter after an oral glucose load and high age-adjusted IGF-I
levels. Three patients (no. 14, 22, and 29) had elevated serum PRL levels.
Clinical data are shown in Table 1. Median age at GK was 46 yr (range,
23–68 yr). Three patients (no. 12, 16, and 19), unsuitable for surgery, un-
derwent GK after medical treatment with somatostatin analogs (SA). In one
patient (no. 16) this treatment obtained shrinkage of the adenoma away
from the optical chiasm, allowing the following treatment by GK. In 27
patients GK was performed 1–18 yr (median, 3 yr) after unsuccessful pi-
tuitary surgery (by transfrontal route in two, no. 4 and 11) and was followed
by medical therapy. Four of these patients (no. 2, 5, 7, and 10) had also
undergone RT. These patients, all irradiated at least 10 yr before GK,
showed stable and persistently elevated GH concentrations.
Twelve patients underwent GK while on treatment with long-acting
SA (no. 5, 9, 10, 15, 17, 19–21, 23, 25, 27, and 29) and 18 off-treatment.
Before GK, seven patients had TSH deficiency (no. 3, 4, 5, 7, 8, 10, and
13), four had ACTH deficiency (no. 3, 4, 10, and 13), four male patients
(no. 2, 3, 4, and 10) had gonadotropin deficiency, seven females were of
menopausal age, and none of the premenopausal women had amenor-
rhea. Posterior pituitary function was normal in all patients.
Methodology of GK treatment
Twenty-seven procedures were performed in a GK model B at one
institution (San Raffaele Hospital, Milan, Italy); the remaining three (no.
22, 23, and 27) were performed at three sites in other countries, with
similar doses and technique.
A Leksell model G stereotactic frame was applied in all patients under
local anesthesia. Imaging was performed within the Leksell frame by
high resolution magnetic resonance imaging in all patients, to define the
pituitary adenoma volume and settle target coordinates. In selected
cases a computed tomography scan was used to overcome geometrical
uncertainties.
In a single patient (treated in 1993 in another institution) dose plan-
ning was performed using graphical software (KULA, AB Elekta, Stock-
holm, Sweden) on a Micro-Vax II computer workstation (Digital Equip-
ment Corp., Westminster, MA); in all others treatment planning was
performed by dedicated three-dimensional simulation software (Leksell
 Plan AB Elekta).
The neurosurgeon and the radiation physicist decided jointly the
treatment isodose, the central dose, and the dose to the margin, with the
foremost consideration being given to the radiation dose received by
optic chiasm, that was always lower than 8 Gy. The median irradiated
volume was 1.43 ml (range, 0.2–3.7). All patients were treated with
multiple isocenters (mean, 8; range, 3–11). The 50% isodose was used in
27 patients (90%). The median margin dose was 20 Gy (range, 15–35).
Patients were discharged from the hospital on the day after treatment.
Each patient gave informed consent after full explanation of the
purpose of the study, which was approved by each local ethic commit-
tee, and the procedures followed were in accordance with the Helsinki
Declaration of 1975 as revised in 1983.
Protocol
Patients were followed-up at regular intervals, every 3–6 months
during the first year and every 6–12 months thereafter. At every visit a
careful clinical and ophtalmological evaluation was performed. Ongo-
ing GH-suppressive treatment was periodically withdrawn (at least for
TABLE 1. Demographic and clinical data
Patient no. Sex Agea (yr) Previous treatmentsb Basal GH(g/liter)
Basal IGF-I
(g/liter)c
Follow-up
(months)
1 M 45 TS (1996/1997) SA 8.0 600 27
2 M 42 TS (1979), RT (1985), SA 35.0 1400 57
3 M 56 TS (1997), SA 5.3 541 13
4 M 25 TC (1995), SA 10 800 60
5 F 50 TS (1986), RT (1986), SA 15.0 375 55
6 F 43 TS (1988), SA 10.0 1100 56
7 F 44 TS (1984), RT (1984), SA 10.0 700 41
8 M 52 TS (1991/1997), SA 14.0 832 24
9 M 27 TS (1994), SA 11 592 24
10 M 58 TS (1986), RT (1987), DA 6.3 697 45
11 M 46 TC (1991), SA 8.0 850 47
12 F 60 SA 3.0 1000 65
13 F 64 TS (1998), SA 20.0 800 24
14 F 46 TS (1993), SA 82.4 994 60
15 F 68 TS (1985), SA 6.4 1216 60
16 M 49 SA 30 910 60
17 F 46 TS (1992), SA 5.5 727 60
18 F 44 TS (1994), SA 2.9 441 48
19 M 36 SA 11 805 48
20 M 39 TS (1998), SA 13.7 648 18
21 F 67 TS (1978), SA 11.7 1622 36
22 M 67 TS (1996), SA 9.5 589 36
23 M 62 TS (1980), SA 11 864 96
24 F 23 TS (1999), SA 16.8 912 12
25 M 51 TS (1993), SA 6.5 665 48
26 F 37 TS (1995), SA 2.7 857 60
27 F 26 TS (1997), SA 25.5 640 36
28 M 38 TS (1996), SA 4.8 460 18
29 F 59 TS (1996), SA 19.6 673 42
30 M 42 TS (1999), SA 7.6 1423 9
a Age at treatment.
b Previous treatments (year in parentheses): TS, transsphenoidal neurosurgery; TC, transcranic neurosurgery; RT, fractionated conventional
radiotherapy; SA, somatostatin analogs; DA, dopamine agonists.
c To convert serum IGF-I values to nanomoles per liter, divide by 7.741.
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3 months) to evaluate the effects of GK. In a few patients with poor
control of disease activity, medical therapy was not withdrawn.
Hormonal data at each control were recorded in two categories,
according to whether medical treatment for acromegaly was still on-
going or had been withdrawn. In Results, data obtained at each follow-up
evaluation are detailed only for patients off medical treatment.
Blood samples were collected in the morning hourly for at least 3 h
after an overnight fast and rest while the patients were supine and
awake, with an indwelling needle inserted in an antecubital vein and
kept patent by slow infusion of saline. GH concentrations were assayed
on each sample (in Results the reported value is the mean of all samples),
and IGF-I levels were determined in the first sample.
In the patients with previously normal pituitary function, assess-
ments of urinary free cortisol (UFC), serum free thyroid hormones, and
testosterone (in males) were performed every 3–12 months. The diag-
nosis of pituitary failure was established on the basis of assays of pe-
ripheral hormones showing values below the normal range. Gonadal
failure in females was considered only if menstrual cycles terminated
before 45 yr with low gonadotropin levels.
GH deficiency was diagnosed when IGF-I levels were lower than the
fifth percentile of age-matched range.
Methods
Serum GH levels were measured by an immunofluorometric assay
(IFMA) method supplied by AutoDelfia purchased from Wallac, Inc.
(Turku, Finland) with standards calibrated against WHO First Interna-
tional Standard 80/505 (1g/liter 2.6 mU/liter). The sensitivity is 0.01
g/liter; the intra- and interassay coefficients of variation are 2% and
1.7%, respectively.
Serum IGF-I was measured by a RIA supplied by Mediagnost (Tu-
bingen, Germany) with minor modifications. The calibration of this RIA
with regard to the WHO International Standard, NIBSC 87/518, yields
a conversion factor of 1.66. This kit is able to measure total IGF-I by
separating IGF-I from IGF-binding protein by acidification in IGF-II
excess. IGF-II cross-reactivity is less than 0.05%; the intra- and interassay
coefficients of variation are 3.2% and 7.4% respectively. In our laboratory
current normal values for IGF-I (5th-95th percentiles) are 115–338 g/
liter in patients 20–30 yr old, 108–323 g/liter in patients 30–40 yr old,
100–307 g/liter in patients 40–50 yr old, 97–294 g/liter in patients
50–60 yr old, and 91–284 g/liter in patients 60–70 yr old. To convert
serum IGF-I values to nanomoles per liter, divide by 7.741.
PRL was measured by IFMA, and patients were considered hyper-
prolactinemic when mean circulating serum PRL levels were higher than
25 g/liter. Also, free T4, testosterone, and UFC were assayed by com-
mercial IFMA methods, UFC after extraction.
Ophtalmological evaluation was performed by Goldmann or com-
puterized perimetry.
Magnetic resonance imaging was performed by Philips Gyroscan
(ACS-NT, Philips Electronic Instruments, Mahway, NJ; 1.5 Tesla) before
GK, 6 and 12 months after GK, and yearly thereafter. The annual ex-
amination was always performed under the same conditions as far as
ongoing treatment or its withdrawal. All scans were reviewed by an
author (M.F.), who was unaware of the clinical and biochemical con-
ditions of the patient. On each scan the largest diameter of the tumor was
measured on coronal [vertical diameter (V)] and axial sections [antero-
posterior (AP) and transverse (T)], calculating the approximate volume
of the adenoma as the volume of a rotating ellipsoid, with the following
formula (18): volume   (V  AP  T)/6. The shrinkage of the tumor
was arbitrarily considered significant when such a volume was reduced
by at least 25%.
The follow-up of tumoral modifications after GK was performed only
in a subgroup of 19 patients, because little remnant volume due to
previous surgery and RT treatments impaired this evaluation in the
other 11 patients.
Statistical analysis
Values are expressed as the median and interquartile range (25–75%)
unless otherwise stated. Analyses were performed using GB-Stat 6.5.4
PPC on raw data or after transformation of hormonal data as a per-
centage of the baseline.
Data were analyzed by parametric or nonparametric tests, depending
on whether they passed preliminary Kolgomorov-Smirnov test for nor-
mality, respectively. Continuous data with normal distribution were
analyzed by t test for paired or unpaired data, ANOVA followed by
Student-Newman-Keuls test, and Pearson correlation test. Continuous
data with uneven distribution were analyzed by Wilcoxon test, Mann-
Whitney test, Kruskal-Wallis test followed by Dunn test, and Spearman
correlation test. Categorical data were analyzed by Fisher’s exact test.
Longitudinal evaluations were performed by Kaplan-Meier method,
and differences between subgroups were evaluated by log-rank test.
All statistical tests were two-tailed, and P  0.05 was considered
significant.
Results
Patients were followed-up for a median period of 46
months (range, 9–96). No patient was lost to follow-up.
Hormonal profile
Five patients (no. 4, 9, 10, 20, and 24) at their last evaluation
were receiving treatment with SA and/or dopamine agonists
due to poor control of the disease despite treatment (on
group).
In the remaining 25 patients, evaluated after withdrawal
of antisecretory treatment (off group), IGF-I values fell from
805 (range, 640–994) to 460 (range, 217–654) g/liter (P 
0.0002). Normal age-matched IGF-I levels were obtained in
7 patients (23% of the whole series; Fig. 1A), 24 (range, 13–30)
months after GK.
GH levels decreased from 10 (range, 6.4–15) to 2.9 (range,
2–5.3) g/liter (P  0.0001), reaching levels below 2.5 g/
liter in 11 (37% of the whole series; Fig. 1B) irradiated 24
(range, 18–28) months before.
Both safe GH and normalized IGF-I levels were achieved
during prolonged off therapy by seven patients (23%). More-
over, in five patients, who maintained high hormonal levels
during medical treatment before GK, the same treatment suc-
ceeded in normalizing GH and IGF-I concentrations after GK.
A longer follow-up is needed to know exactly the final endo-
crinological outcome of these patients. Neither basal hormonal
levels, volume of the adenoma, length of follow-up, nor dose of
radiation were different between patients who achieved and
those who did not achieve hormonal normalization.
Hormonal levels before treatment, dose of radiation, and
length of follow-up were not different between patients in
the off group and those in the on group.
The longitudinal evaluation showed that 1 yr after GK, GH
and IGF-I concentrations were 62% (range, 39–79%) and 61%
(range, 51–101%) of basal levels, respectively. The respective
figures were 49% (range, 28–76%) and 57% (range, 34–73%)
after 3 yr, and 25% (16–64%) and 41% (28–47%) after 5 yr
(Fig. 2). By Kaplan-Meier analysis, the rate of pathological
GH/IGF-I levels fell from 93% at 1 yr to 76% at 3 yr to 70%
at 5 yr (Fig. 3).
The outcome of the 4 patients previously submitted to RT
was not different from that of the whole series, that of the
patients not previously submitted to neurosurgery, or that of
the hyperprolactinemic patients. No difference in outcome
was observed between patients who had withdrawn SA dur-
ing irradiation and those still receiving treatment while un-
dergoing GK. In particular, 7 of 18 patients of the former
group attained safe GH levels compared with 4 of 12 of the
latter (P  0.53, by Fisher’s test; P  0.85, by log-rank). The
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respective figures for IGF-I normalization were 4 and 3. Nei-
ther basal hormonal levels before GK nor length of follow-up
were different between the 2 subgroups. Sex and age did not
influence the outcome of treatment in our range of age
groups. No patient had recurrence or worsening of disease.
Tumor size
In no patient was progression of tumor growth observed
during follow-up. The median volume of the adenoma de-
creased to 0.3 (range, 0.1–0.4) ml (P  0.001). Tumor size
reduction greater than 25% of basal volume occurred in 11
(no. 2, 4, 6, 11, 12, 16–18, 22, 29, and 30) of the 19 assessable
patients (58%) 24 (range, 12–36) months after GK. Individual
tumor shrinkage ranged between 6–77% of the basal volume
(median, 18%). There was a direct correlation between basal
and final volume ( 0.5975; P 0.0113), but no relationship
between tumor shrinkage and hormonal changes. The rate of
tumor shrinkage increased from 28% at 1 yr to 79% at 4 yr,
by Kaplan-Meier test (Fig. 3).
Adverse effects
Acute toxicity. One patient (no. 6) developed severe headache
and nausea immediately after GK, which recovered within 1
wk with steroid treatment.
Chronic effects. No visual deficit was reported in any patient.
Visual fields, repeated in all patients at the last follow-up
visit, were unchanged. Prospective assessment of cognitive
functions was not performed, but neither the patients nor
their relatives reported development of memory impairment
FIG. 1. Individual IGF-I (A) and GH
(B; log scale; the horizontal line is set at
2.5 g/liter) levels before (empty sym-
bols) and after (full symbols) GK (at the
final evaluation). In each panel pa-
tients who were submitted to GK while
on or off SA are depicted on the left and
the right, respectively. To convert se-
rum IGF-I values to nanomoles per li-
ter, divide by 7.741.
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on formal inquiry. New anterior pituitary failure was ob-
served in two patients. In patient 12 hypoadrenalism devel-
oped 6 yr after GK, when acromegaly was still active. In
patient 8 hypogonadism and hypoadrenalism developed 2 yr
after GK, concomitantly with normalization of GH and IGF-I
hypersecretion, adding to preexisting hypothyroidism. In
the other patients no new deficiency was observed beyond
minor changes (Fig. 4). No patient developed GH deficiency.
Discussion
The relative role of alternative therapeutic options in ac-
romegalic patients after surgical failure or in those unsuitable
for or unwilling to undergo surgery is still debated, as no
single treatment modality seems to afford a cure in all pa-
tients. Medical treatment with long-acting SA is very effec-
tive in most patients (19), but it is expensive and life-long.
The efficacy of RT, denied by some researchers (4, 20), is still
controversial; its effects are very delayed and are often ac-
companied by a high incidence of side-effects (21, 22), such
as hypopituitarism, cerebral necrosis, and a low possibility
of damage to optic pathways, neuropsychological impair-
ment and perhaps development of secondary tumors (13, 14,
23). Alternative modalities of radiation delivery, such as
conformal radiotherapy by modified linear accelerators (24,
FIG. 2. Percent decrease (median and interquartile) of GH (squares and continuous line) and IGF-I (diamonds and broken line) after GK
(baseline normalized to 100%).
FIG. 3. Kaplan-Meier analysis: achievement of GH safe levels is depicted by squares and continuous line, IGF-I normalization by diamonds
and dotted line, tumor shrinkage by circles and dotted-broken line.
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25) or particle accelerators (26), are still under evaluation or
are not widely available, respectively. With these techniques
the incidence of cerebral necrosis, neurocognitive dysfunc-
tions, and optic damage is reported to be near nil.
In the present series GK produced safe GH levels and
age-matched IGF-I normalization in about 25% of our pa-
tients within 5 yr. The doses employed have uniformly been
decided in a defensive approach, backcalculating from the
dose considered safe to the sensitive structures (in the order:
optic pathways, lower stem, oculomotor nerves, and healthy
pituitary) (27, 28) and covering the adenoma by whichever
dose was allowed. As a progressive unrestrained decline in
hormonal levels was observed in most patients, a more pro-
longed follow-up is needed to better evaluate the real effec-
tiveness of GK in acromegaly.
A comparison with published results is difficult, because
most series are either methodologically inhomogeneous or
define cure by outdated or unspecified criteria (29–33). Only
a few employ modern criteria of cure, as defined in the
consensus conference (34), i.e. the achievement of basal GH
levels less than 2.5 g/liter and suppressibility less than 1
g/liter after oral glucose load combined with normal age-
matched IGF-I levels. Using these criteria, published results
about GH and IGF-I normalization vary from 82% (14 of 17)
described by Ikeda et al. (35) to 60% (6 of 10) by Jackson and
Nore´n (36), 43% (39 of 91) by Vladyka et al. (37), and 29% (17
of 59) by Vance (38). Landolt and colleagues (39) reported a
mean time of IGF-I normalization of 2.9 yr in keeping with
our results. GK was used in most patients as a second step
after surgical failure, i.e. in a selected population, that might
not be representative of the previously untreated acrome-
galic patients. The decrease in GH and IGF-I levels in the
three patients treated with GK as primary treatment did not
differ from that in surgically treated patients. However, this
sample is too small to draw any definitive conclusion.
For the comparison with results obtained by RT, it should
be underlined that we did not perform a randomized com-
parative study of the two therapeutic modalities. The pre-
vious experience obtained by RT in acromegalic patients by
the authors of this paper is not homogeneous; Epaminonda
et al. (23) reported its effectiveness, but with the burden of
hypopituitarism in a considerable portion of the series,
whereas Cozzi and colleagues (20) observed its substantial
failure, due perhaps to methodological differences in the
irradiation procedure. It may be of interest that the per-
centage of patients who normalized IGF-I after a median
follow-up similar to that of the present study (4–5 yr) was
24% in the case studies of Epaminonda et al. (23) (pretreat-
ment GH, 20.2 g/liter) and 6.7% in the case studies of Cozzi
et al. (20) (pretreatment GH, 18 g/liter). Only Landolt et al.
(40) reported the direct comparison of the two techniques,
showing that the percent decrease in GH/IGF-I values from
baseline was steeper by GK compared with RT. It is fair to
say that a correct comparison should be performed with
modern techniques, allowing conformation and precise fo-
cusing of radiation on tumoral tissue.
In contrast with previous data obtained by RT, showing
better outcome in acromegalic patients whose basal GH lev-
els were lower (21, 23), in this series the control of hormonal
hypersecretion was not dependent on basal GH values.
The observation that four patients reached safe GH levels,
but still had high IGF-I concentrations, is in keeping with
several previous findings after RT (4, 23) and might be ex-
plained by the persistence of a lower, but continuously re-
leased, tonic GH secretion capable of inducing an exagger-
ated stimulation of hepatic IGF-I synthesis (41, 42).
No difference in the outcome was observed between the
patients who received SA at the time of GK application and
those who did not, in contrast with Landolt et al.’s suggestion
of a radioprotective effect of octreotide (43), confirmed later
in the retrospective evaluation of another series of patients
submitted to RT (20). However, this study was not designed
as a prospective randomized one and, even if the two sub-
groups seem balanced for age, hormonal levels, and tumor
volume, a definitive answer to the issue of whether it is better
to administer ionizing radiation to resting or active cells
cannot be given.
In our series GK was very effective in controlling tumor
FIG. 4. Percent change from baseline (median, interquartile) at the last evaluation after GK for testosterone, UFC, free T4 (FT4), and PRL levels.
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mass, as demonstrated by the lack of further growth of the
adenoma in all patients and by the outstanding shrinkage in
most. The control of tumoral growth was already reported in
virtually all acromegalic patients, with shrinkage in many
(30, 31, 44, 45). The only exception was reported by Pan and
colleagues (46), who observed a volumetric increase in the
tumor in 3 of 65 patients. A word of caution about size
reduction is mandatory. It cannot be ruled out that this effect
may be linked to concomitant SA treatment carried on
throughout the follow-up period in most patients. On the
other hand, neuroradiological evaluation was always per-
formed in the same conditions as those used for treatment
withdrawal or its prolongation, to minimize drug interfer-
ence. Moreover, several reports showed that tumor shrink-
age is much less evident or negligible in patients treated with
SA after surgery compared with patients treated with these
drugs as first line treatment (47).
The dissociation between the control of tumor growth
and that of hormonal hypersecretion is well known. In fact,
it has been reported (37, 48) that the dose of radiation
to be administered to the tumor is different if the goal of
therapy is to reverse an endocrinopathy or merely to
halt growth.
Finally, we stress that the procedure seems safe: no major
side-effect was observed, no visual impairment developed,
and the occurrence of hypopituitarism was very rare. Lim-
iting factors in the delivery of an ablative radiation dose
include its proximity to the optic apparatus and the size of
the tumor. To avoid visual impairment, the dose of radiation
to the optic chiasm should not exceed 10 Gy, and our choice
was in agreement with the most restrictive cut-off of 8 Gy to
the visual pathways (27). Accordingly, pituitary tumors with
suprasellar extension that abut the optic apparatus cannot
receive a tumor ablative dose without the risk of compro-
mising vision. The same restrictions do not apply to tumors
extending laterally into the cavernous sinus, where cranial
nerves III, IV, V, and VI are much less susceptible to radiation
damage than is the optic nerve. In comparison with RT, GK
permits conformation of the radiation to the tumor shape,
thus limiting the radiation exposure of surrounding tissue.
Literature data report the rare occurrence of visual damage
(30, 49), which we did not observe, and the variable occur-
rence of hypopituitarism, ranging from less than 5% (37),
concordant with us, to 10–29% (31, 38, 50). These differences
may be explained by the neurosurgeon’s expertise.
As for the development of secondary tumor, previously
described as a rare event in the field of irradiation with RT
(13, 14, 23), it has never been observed after GK, even after
a follow-up longer than 30 yr (51).
Patients who previously underwent RT did not develop
distinctive adverse effects; their hormonal pattern was sim-
ilar to those of the remaining patients. Thus, previous un-
successful RT does not seem to constitute a restriction to GK,
as previously reported (37, 40).
In conclusion, our data show the effectiveness of GK in
acromegalic patients, both on the control of hormonal hy-
persecretion and on tumoral mass. It appears to be at least as
efficacious and probably safer than conventional RT.
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